

Special Issue

Structure and Cell Biology of Viral Infection

Message from the Guest Editor

To cover the latest update in the field of virology, we would like to invite you to submit your original research or review articles on fundamental structures within cell biology, as well as the advanced clinical studies on commercial drug development. The interesting areas for the specific Special Issue are 3D structural-based design together with cell-based technology for monoclonal antibody discovery, antiviral drugs, and vaccines to prevent viral infections and engineering viral vectors for gene and CAR-T cell therapy. We would like to cover various viruses such as: (1) coronavirus as the cause of the recent pandemic; (2) HIV/SIV as the most advanced research in the antiviral therapy and vaccine development; (3) adenovirus as viral vectors for vaccine and gene delivery; (4) lentiviral vectors as major tools for CAR-T cells in oncology; (5) AAV as the major delivery tool for gene therapy in rare diseases; and (6) other viruses or emerging viruses with implications for therapeutic development.

Guest Editor

Dr. Hung V. Trinh

Genezen, 9900 Westpoint Dr, Suite 128, Indianapolis, IN 46256, USA

Deadline for manuscript submissions

closed (31 August 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/117932

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).